Myriad Posts 21 Percent Revenue Growth for Q3 | GenomeWeb

NEW YORK (GenomeWeb News) – Myriad Genetics reported after the close of the market Tuesday that its third-quarter revenues increased 21 percent year over year, with sales of the firm's BART test jumping nearly 400 percent.

The Salt Lake City-based molecular diagnostics company brought in total revenues of $156.5 million for the three months ended March 31, compared to $129.8 million for the third quarter of 2012. It beat the consensus Wall Street estimate for revenues of $148.3 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Genome editing is also bringing up questions when applied to farm animals, the New York Times reports.

Through a transcriptome study, researchers home in on the activity of inflammation-linked genes in chronically lonely people.

Determining who is and is not an author and where a researcher should fall on a list of authors can be a tricky task, Nature News writes.

In PNAS this week: variant protective against Alzheimer's disease, effect of whole-genome duplication on methylation in rice, and more.